HomeCompareMORF vs SPHD

MORF vs SPHD: Dividend Comparison 2026

MORF yields 3.51% · SPHD yields 4.33%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SPHD wins by $1.4K in total portfolio value
10 years
MORF
MORF
● Live price
3.51%
Share price
$56.99
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.1K
Annual income
$439.80
Full MORF calculator →
SPHD
SPHD
● Live price
4.33%
Share price
$49.34
Annual div
$2.14
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.5K
Annual income
$571.32
Full SPHD calculator →

Portfolio growth — MORF vs SPHD

📍 SPHD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMORFSPHD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MORF + SPHD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MORF pays
SPHD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MORF
Annual income on $10K today (after 15% tax)
$298.30/yr
After 10yr DRIP, annual income (after tax)
$373.83/yr
SPHD
Annual income on $10K today (after 15% tax)
$367.92/yr
After 10yr DRIP, annual income (after tax)
$485.62/yr
At 15% tax rate, SPHD beats the other by $111.79/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MORF + SPHD for your $10,000?

MORF: 50%SPHD: 50%
100% SPHD50/50100% MORF
Portfolio after 10yr
$25.8K
Annual income
$505.56/yr
Blended yield
1.96%
📊

Analyst Conviction Gap

Where Wall Street is split right now

MORF
No analyst data
Price Target
$57.00
+0.0% upside vs current
Range: $57.00 — $57.00
Altman Z
60.9
Piotroski
2/9
SPHD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MORF buys
0
SPHD buys
0
No recent congressional trades found for MORF or SPHD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMORFSPHD
Forward yield3.51%4.33%
Annual dividend / share$2.00$2.14
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$25.1K$26.5K
Annual income after 10y$439.80$571.32
Total dividends collected$4.0K$5.1K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: MORF vs SPHD ($10,000, DRIP)

YearMORF PortfolioMORF Income/yrSPHD PortfolioSPHD Income/yrGap
1← crossover$11,051$350.94$11,133$432.85$82.00SPHD
2$12,187$362.45$12,363$450.36$176.00SPHD
3$13,414$373.56$13,695$467.39$281.00SPHD
4$14,737$384.26$15,138$483.90$401.00SPHD
5$16,163$394.55$16,697$499.88$534.00SPHD
6$17,699$404.42$18,382$515.31$683.00SPHD
7$19,352$413.88$20,198$530.17$846.00SPHD
8$21,129$422.92$22,157$544.46$1.0KSPHD
9$23,040$431.56$24,266$558.18$1.2KSPHD
10$25,092$439.80$26,536$571.32$1.4KSPHD

MORF vs SPHD: Complete Analysis 2026

MORFStock

Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; and preclinical trial to treat idiopathic pulmonary fibrosis and fibrosis diseases. The company is also developing avß6 for the treatment of fibrotic diseases, and avß8 to treat solid tumors, as well as various other products. Morphic Holding, Inc. has a research collaboration with Engitix Ltd for the identification of Morphic integrin technology amenable targets in fibrostenotic IBD; a collaboration agreement with Schrödinger, LLC for integrin targets; and a license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. It also has collaboration agreements with AbbVie Biotechnology Ltd and Janssen Pharmaceuticals, Inc. to discover or develop integrin-based therapeutics. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Full MORF Calculator →

SPHDETF

The Invesco S&P 500 High Dividend Low Volatility ETF (Fund) is based on the S&P 500 Low Volatility High Dividend Index (Index). The Fund will invest at least 90% of its total assets in common stocks that comprise the Index. Standard & Poor's compiles, maintains and calculates the Index, which is composed of 50 securities traded on the S&P 500 Index that historically have provided high dividend yields and low volatility. The Fund and the Index are rebalanced and reconstituted semi-annually, in January and July.

Full SPHD Calculator →
📬

Get this MORF vs SPHD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MORF vs SCHDMORF vs JEPIMORF vs OMORF vs KOMORF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.